What is BioLoomics?
BioLoomics operates at the intersection of biotechnology and advanced engineering, specializing in the development of next-generation Super-ADCs (Antibody-Drug Conjugates). By leveraging sophisticated methodologies such as Directed Evolution, the company provides critical solutions for the pharmaceutical and life sciences sectors. Their market position is defined by a commitment to high-precision therapeutic development, aiming to address complex medical challenges through innovative molecular engineering. The company maintains a rigorous focus on scientific integrity and user-centric research frameworks, ensuring that their technological advancements remain at the forefront of the industry.
The firm's operational model is built upon the integration of data-driven computation and biological research, allowing for the rapid iteration of therapeutic candidates. As a key player in the biotech ecosystem, BioLoomics serves as a vital partner for enterprises seeking to enhance their drug discovery pipelines with high-efficacy, targeted delivery systems.
How much funding has BioLoomics raised?
BioLoomics has raised a total of $8.7M across 1 funding round:
Angel/Seed
$8.7M
Angel/Seed (2023): $8.7M with participation from Innovation Endeavors, Horizons Ventures, and BoxOne Ventures
Key Investors in BioLoomics
Innovation Endeavors
An early-stage venture capital firm that invests in visionary founders and transformational technologies, utilizing a Super Evolution thesis to drive industry-wide change.
Horizons Ventures
A firm focused on deep science and technology investments, dedicated to supporting projects that aim to create significant, positive advancements for humanity.
BoxOne Ventures
A venture entity operating within the financial services and transaction processing sector, providing strategic capital to support emerging growth companies.
What's next for BioLoomics?
With this major enterprise-level funding, BioLoomics is poised to scale its Directed Evolution programs and expand its laboratory infrastructure. The strategic allocation of capital will likely focus on clinical trial preparation and the optimization of its Super-ADC platform. By strengthening its research capabilities, the company aims to solidify its competitive advantage in the global biotechnology market, potentially attracting further institutional backing as it transitions from a research-heavy entity to a clinical-stage innovator. The focus remains on achieving long-term scalability and delivering transformative therapeutic outcomes.
See full BioLoomics company page
